Document Detail

A case of abatacept associated neutrophilic dermatosis and a review of the literature.
MedLine Citation:
PMID:  25117161     Owner:  NLM     Status:  In-Data-Review    
Abatacept is a novel biological agent that dampens the immune response by blocking the co-stimulation of T-cells, thus downregulating T-cell activation. It is currently approved for the treatment of rheumatoid arthritis (RA). The group of novel immunomodulatory agents, referred to as biologics, have now been used extensively, with established safety and side-effect profiles. There are, however, increasing reports of adverse paradoxical reactions, most notably resulting from anti-tumour necrosis factor (TNF) therapy. While cutaneous adverse reactions to abatacept are rare, there are a few reports of such paradoxical reactions. We report a case of an idiosyncratic paradoxical neutrophilic dermatosis associated with the use of abatacept.
Shevya Manjri Tiwari; Benjamin A Wood; Theresa Skender-Kalnenas; Nicola Cook
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Australasian journal of dermatology     Volume:  55     ISSN:  1440-0960     ISO Abbreviation:  Australas. J. Dermatol.     Publication Date:  2014 Aug 
Date Detail:
Created Date:  2014-08-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0135232     Medline TA:  Australas J Dermatol     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  214-7     Citation Subset:  IM    
Copyright Information:
© 2014 The Australasian College of Dermatologists.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Abstracts.
Next Document:  Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to...